| answer text |
<p>The National Institute for Health and Care Excellence (NICE) is currently updating
its guideline on the diagnosis and management of early and locally advanced breast
cancer. The use of adjuvant bisphosphonates has been identified as one of the key
areas that will be covered in the update which is scheduled for publication in July
2018. In the meantime, NICE has published an evidence summary on the use of adjuvant
bisphosphonates in early breast cancer. NHS England expects clinical commissioning
groups to take account of NICE guidelines and local population needs when making commissioning
decisions.</p>
|
 |
